Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC2156119J vs sorafenib in MET-positive advanced hepatocellular carcinoma
CTR20140873Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tepotinib in hepatocellular carcinoma (HCC), sponsored by Merck KGaA. Started May 2015; status: completed.
02
Drugs
tepotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20140873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140873.